Meteorologists were amazed by how fast Ida strengthened.
The storm had evolved swiftly from a worrisome disturbance to possibly the most devastating to strike Louisiana since Hurricane Katrina.
By Alyssa Lukpat and Tariro Mzezewa
Biotech Stocks Facing FDA Decision In September 2021
As August draws to a close, let us take a look back at some of the regulatory headlines from that eventful month and look forward to what September has in store.
A new treatment for Pompe disease, Sanofi’s Nexviazyme, was approved by the FDA on Aug.6. The company already has one approved Pompe disease drug, which is sold as Myozyme in Europe and Lumizyme in the U.S.
The U.S. regulator approved a novel indication for Xywav for idiopathic hypersomnia (IH) in adults on Aug.12. This drug is already approved for the treatment of cataplexy or excessive daytime sleepiness in patients seven years or older with narcolepsy.
On Aug.23, Pfizer-BioNTech COVID-19 Vaccine became the first to receive full FDA approval for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine will now be marketed as Comirnaty and will also continue to be available under emergency use authorization, including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals.
Now, let’s take a look at the biotech stocks facing FDA decision in September.
Motorcycle passenger killed, driver injured in Denver hit-and-run crash
Police in Denver are investigating a fatal hit-and-run crash involving a vehicle and a motorcycle that occurred early Sunday morning. The driver of the vehicle took off after the crash.
It happened on East Evans Avenue at South Williams Street, about a block west of the University of Denver campus, according to a tweet from the Denver Police Department.
The crash between the vehicle and the motorcycle resulted in the death of a woman, a passenger on the motorcycle, and serious injuries to the motorcycle driver, an adult male.
Read the full story from our partner at thedenverchannel.com.
Lantern Pharma: FDA Grants Additional Orphan Drug Designation For LP-184 – Quick Facts
Clinical-stage biopharmaceutical company Lantern Pharma (LTRN) said the FDA has granted LP-184 Orphan Drug Designation for the treatment of glioblastoma multiforme and other malignant gliomas. Previously, LP-184 was granted Orphan Drug Designation for the treatment of pancreatic cancer.
LP-184 is a small molecule drug candidate and next generation alkylating agent that preferentially damages DNA in cancer cells that over-express certain biomarkers or that harbor mutations in DNA repair pathways.
Shares of Lantern Pharma were up 5% in pre-market trade on Monday.
Review: ‘Laetitia,’ a French True-Crime Gem, Comes to HBO
The Oscar-winning documentarian Jean-Xavier De Lestrade turns to fiction to tell a story of grisly murder in western France.
By Mike Hale
Pemex restores oil output suspended due to platform fire
MEXICO CITY, Aug 30 (Reuters) – Mexican state oil firm Petroleos Mexicanos (Pemex) said on Monday that its has resumed 421,000 barrels per day in oil production and brought back online 125 wells following a deadly fire at an offshore platform on Aug. 22.
The accident in the southern Gulf of Mexico at the offshore platform that is part of Pemex’s most productive oil field Ku-Maloob-Zaap, knocked out about 25% of Mexico’s total production.
Maruti Suzuki India to hike prices across models from September
At present Maruti Suzuki sells a range of models priced between ₹2.99 lakh and ₹12.39 lakh
The country’s largest carmaker Maruti Suzuki India on Monday said it will hike prices across models from next month amid rising input costs.
In a regulatory filing, the company said, "…. over the past year the cost of company’s vehicles continue to be adversely impacted due to increase in various input costs." Hence, it has become imperative to pass on some impact of the additional cost to the customers through a price rise, it added.
"The price rise has been planned across models in September 2021," Maruti Suzuki India said.
At present the company sells a range of models from entry-level hatchback Alto to S-CROSS, priced between ₹2.99 lakh and ₹12.39 (ex-showroom prices Delhi) lakh, respectively.
Zebra Technologies Plans To Acquire Antuit.ai – Quick Facts
Zebra Technologies (ZBRA) announced Monday that it intends to acquire antuit.ai, a provider of artificial intelligence (AI)-powered Software-as-a-Service (SaaS) solutions specific to forecasting and merchandising for the retail and CPG industries.
Antuit.ai, owned by a consortium led by Goldman Sachs Asset Management, utilizes AI and machine learning algorithms to ensure its customers have the right product in the right place, at the right time, at the right price based on the current state of the supply chain, store inventory, and consumer demand.
Incorporating antuit.ai’s AI-powered demand forecasting solution into Zebra’s SaaS portfolio will enable retailers and consumer products companies to combine planning and execution to optimize margins and drive revenue growth.
Antuit.ai enables retailers to deliver on their omnichannel strategy by increasing margins with effective prices and promotions, as well as optimizing inventory allocations and order fulfillment.
With antuit.ai, consumer products companies can maximize forecast accuracy; anticipate consumer demand to meet retailers’ service level, shelf-level, store-level, and e-commerce orders; optimize pricing and trade promotions; and unify sales, trade and demand planning.
Antuit.ai will be the third SaaS company acquired by Zebra that has been recognized as a top solution provider in the RIS Software Leaderboard over the last two years.